Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 5 versus ORETON METHYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 5 versus ORETON METHYL.
ANDROID 5 vs ORETON METHYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Methyltestosterone is a synthetic androgen that binds to androgen receptors, activating transcription of androgen-responsive genes, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
10-50 mg orally or buccally 1-3 times daily; or 25-100 mg IM every 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Terminal half-life approximately 2.7–3.8 hours; brief due to rapid hepatic metabolism.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Primarily renal as conjugated metabolites; ~90% urinary, ~6% fecal within 4 days.
Category C
Category C
Androgen
Androgen